US Officials to Correct Misinformation on Nicotine E-Cigarettes

Dec.13.2022
US Officials to Correct Misinformation on Nicotine E-Cigarettes
US tobacco researchers ask CDC for correct information on e-cigarettes, with health officials correcting misleading public health statements.

Tobacco researchers in the United States have consulted with the Centers for Disease Control and Prevention (CDC). The US Secretary of Health will address some incorrect information released by public health agencies regarding nicotine e-cigarettes.


US Health Secretary Vivek Murthy has recently launched an initiative to reduce the spread of health misinformation in light of the COVID-19 pandemic. As part of this effort, he has advised public health institutions such as the Centers for Disease Control and Prevention (CDC) to stop promoting inaccurate information about electronic cigarettes. For instance, the CDC had disseminated misleading information about the lung injuries caused by e-cigarettes in 2019 (EVALI), and the Health Secretary's report about youth e-cigarette use in 2016 had wrongly claimed that nicotine e-cigarettes were the most commonly used among young people.


The call was made in an editorial published in the Addiction journal. It was co-written by Michael Pesko, a health economist at Georgia State University, along with colleagues from Harvard Medical School, Pennsylvania State University, the Medical University of South Carolina and the University of Michigan. Tom Miller, the former chairman of the Truth Initiative board and Iowa's attorney general, was also a co-author.


The author of the editorial explained that the Center for Disease Control (CDC) named the lung injury of 2019 related to the usage of e-cigarettes as "EVALI" and refused to change the name, which led to widespread attention and misunderstanding from the public and scientific community about the cause of the disease.


It has been reported that the current director of the FDA's Center for Tobacco Products, Brian King, coined the term "EVALI." King is a staunch opponent of nicotine e-cigarettes and was formerly an employee in the smoking and health office at the Centers for Disease Control and Prevention.


The name EVALI has been indirectly responsible for the deaths of 68 people and has sent thousands to hospital, as they were not given a clear warning by public health officials about the risks associated with unregulated electronic cigarettes containing THC oil.


According to the author, all evidence indicates that the illegal tetrahydrocannabinol (THC) e-cigarettes contaminated with vitamin E acetate are the main risk factor for illness, but there is no research indicating any chemicals found in nicotine e-cigarettes. Vitamin E acetate is insoluble in nicotine e-liquid and has never been detected in nicotine e-cigarettes.


The author suggests that despite evidence to the contrary, the Center for Disease Control (CDC) continues to include e-cigarettes in the EVALI designation. This naming convention has had an impact on news reporting and has contributed to a distorted belief among consumers that using nicotine e-cigarettes is risky.


In 2021, the same author officially requested that the Centers for Disease Control and Prevention trace a change in the name "EVALI," removing "e-cigarette" from the name and adding "adult THC.


2FIRSTS will continue to report on this topic, with further updates available on the "2FIRSTS APP". Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Malaysia's Poisons Board Backs New Vape Nicotine Exemption After Unanimously Opposing 2023 Proposal
Malaysia's Poisons Board Backs New Vape Nicotine Exemption After Unanimously Opposing 2023 Proposal
Malaysia's Poisons Board has endorsed Health Minister Dzulkefly Ahmad's proposal to exempt liquid nicotine used in vaping products from the Poisons List, according to a November 2, 2026, report by CodeBlue. The Board unanimously opposed a similar proposal in 2023, but the government proceeded with the exemption. The Kuala Lumpur High Court invalidated the 2023 decision in May 2026, and the government withdrew its appeal in August. No new ministerial order has been published. The development raises questions about the interaction between Malaysia's two regulatory frameworks and the treatment of RM354.51 million in excise duties collected on e-cigarette and vape products between May 2023 and June 11, 2026.
Regulations
Nov.03
Special Report|CrossBar's High-Puff Vapes Draw Attention on Pennsylvania's 163-Product Directory as Link Between Earlier 1.3mL PMTA Filings and New 13mL Products Remains Unclear
Special Report|CrossBar's High-Puff Vapes Draw Attention on Pennsylvania's 163-Product Directory as Link Between Earlier 1.3mL PMTA Filings and New 13mL Products Remains Unclear
Pennsylvania began enforcing its electronic nicotine delivery system directory restrictions on October 19, 2026. Among 163 product listings recorded before enforcement, four CrossBar 20K disposables stood out with 13mL capacity, advertised puff counts of up to 20,000 and a flattened design distinct from conventional pod systems and compact disposables. Historical records identify earlier 1.3mL CrossBar products associated with Romo LLC, while newer 13mL products appeared in several state directories beginning in 2025 under entities including Blue Nine LLC. PMTA compliance expert Mr. K identified amendments and application ownership transfers as possible regulatory mechanisms, although neither has been confirmed in this case. Separately, Reynolds' $7.5 million acquisition of 16 PACHA products and related assets illustrates the commercial value of products linked to historic PMTA submissions.
Special Report
Oct.22
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Product | JTI Introduces Fully Dissolvable PERLZ Nicotine Pearls in UK, Expands Range From 30-Pearl Dispensers to 10-Pearl Sachets
Japan Tobacco International (JTI) has introduced PERLZ nicotine pearls in the UK, expanding its oral nicotine portfolio beyond conventional nicotine pouches. The fully dissolvable, multi-layer pearls are placed under the tongue and come in Mint and Berry flavors at concentrations of 1mg/g and 2mg/g, equivalent to approximately 0.3mg and 0.5mg of nicotine per pearl. UK retailer Haypp published four 30-pearl dispenser listings on July 31, 2026, followed by three 10-pearl sachet products on August 17. The dispensers retail for £6.50, while the sachets cost £2.50.
product
Oct.12
White House Pulls Heidi Overton's FDA Nomination as Vaccine, Abortion Pill and Vaping Disputes Fuel Senate Opposition
White House Pulls Heidi Overton's FDA Nomination as Vaccine, Abortion Pill and Vaping Disputes Fuel Senate Opposition
The White House withdrew Heidi Overton's nomination to lead the U.S. Food and Drug Administration (FDA) on November 17, 2026, a day before a scheduled Senate committee vote. Overton faced questions from Republican and Democratic senators over vaccines, abortion medication and flavored nicotine products. In May, the FDA granted its first marketing authorizations for non-tobacco, non-menthol e-cigarette flavors, including mango and blueberry pods from Glas. Republican Senator Susan Collins challenged recent authorizations for flavored vaping and nicotine pouch products during Overton's September confirmation hearing. The FDA remains under Acting Commissioner Kyle Diamantas.
FDA
Nov.18
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
Product | KUMI SCENIC 50K Offers Nicotine and 6-Methyl Nicotine Versions as 6-MN Products Appear in Multiple U.S. State Directories, With Louisiana Listing FDA Exemption
An October 2026 review of U.S. state vapor product directories found KUMI 6 SCENIC 50K listed in Louisiana and Nebraska. Louisiana classifies 20 related product entries as “FDA EXEMPTION.” The SCENIC platform is marketed in both conventional nicotine-salt and NoNic6 formulations, each advertised with 22mL e-liquid capacity and up to 50,000 puffs. U.S. wholesaler Midwest Goods listed both versions in August 2025 with a suggested retail price of $19.99 each. The NoNic6 version is associated with 6-methylnicotine and is also marketed by some distributors as “nicotine-free.”
product
Oct.27